Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

BACKGROUND: We performed a randomized phase 3 study of trabectedin versus dacarbazine in previously‐treated patients with liposarcoma/leiomyosarcoma (LPS/LMS). METHODS: Patients were randomized 2:1 to trabectedin (n = 384) or dacarbazine (n = 193) administered intravenously every 3 weeks. The primar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Patel, Shreyaskumar, von Mehren, Margaret, Reed, Damon R., Kaiser, Pamela, Charlson, John, Ryan, Christopher W., Rushing, Daniel, Livingston, Michael, Singh, Arun, Seth, Rahul, Forscher, Charles, D'Amato, Gina, Chawla, Sant P., McCarthy, Sharon, Wang, George, Parekh, Trilok, Knoblauch, Roland, Hensley, Martee L., Maki, Robert G., Demetri, George D.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6771856/
https://ncbi.nlm.nih.gov/pubmed/31173362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32117
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados